查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1941132

HIV相关脂肪萎缩市场－全球产业规模、份额、趋势、机会及预测（按类型、给药途径、分销管道、地区和竞争格局划分，2021-2031年）

HIV-associated Lipodystrophy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球 HIV 相关脂肪代谢障碍市场预计将从 2025 年的 1.8582 亿美元成长到 2031 年的 2.2862 亿美元，复合年增长率为 3.52%。

脂肪萎缩症是一种代谢综合征，伴随脂肪异常重新分布，包括脂肪萎缩和脂肪增生。它通常是抗逆转录病毒疗法的副作用。全球HIV感染族群的持续成长以及抗逆转录病毒疗法（ART）计画的显着扩展是导致脂肪萎缩症发病率上升的主要原因，这延长了患者的平均寿命，同时也增加了他们长期承受副作用的风险。此外，临床上需要解决与代谢异常相关的心血管风险，这也促使人们寻求超越单纯美观问题的有效管理策略。

市场概览
预测期 2027-2031
市场规模：2025年 1.8582亿美元
市场规模：2031年 2.2862亿美元
复合年增长率：2026-2031年 3.52%
成长最快的细分市场 药物治疗
最大的市场 北美洲

然而，已通过核准疗法的高成本和不完善的报销体系严重阻碍了市场扩张，限制了中低收入地区患者的治疗机会。儘管需要持续治疗的人群不断增长，但这种经济障碍仍然是一项重大挑战。根据联合国爱滋病规划署（UNAIDS）的数据，到2024年底，全球将有约3,160万人接受抗逆转录病毒疗法，这将显着增加面临治疗相关脂肪代谢障碍风险的人。

市场驱动因素

全球爱滋病毒感染率的上升是市场需求的根本驱动因素，因为长期生存者的增加与代谢併发症发生率的增加直接相关。随着抗逆转录病毒疗法延长了患者的寿命，他们接受救命治疗的时间也随之延长，这累积了发生脂肪重新分布症候群（例如脂肪萎缩和脂肪增生）的风险。不断扩大的患者群体使得持续的医疗需求促使人们寻求干预措施来控制这些慢性副作用。根据联合国爱滋病规划署于2024年7月发布的《2024年概况介绍》，截至2023年，全球约有3,990万人感染爱滋病毒，这意味着潜在的庞大病患群体需要接受治疗。此外，根据美国疾病管制与预防中心（CDC）2024年的报告，到2022年底，美国预计将有120万人感染爱滋病毒，凸显了高价值地区市场的强劲需求。

同时，新型疗法和皮肤填充剂的进步正推动收入成长，治疗方案也从基础管理发展到有效的美容和代谢修復。针对生长激素释放因子和专用丰盈填充剂的商业化，正促使更多患者接受这些疗法，以减轻与疾病相关的身体变化所带来的社会污名。该行业展现出强劲的财务表现，显示医疗系统和患者都愿意投资于这些解决方案。例如，Theratechnologies Inc. 在 2024 年 10 月发布的「2024 年第三季财报会议纪要」中报告称，用于减少 HIV 感染患者腹部脂肪的注射疗法 EGRIFTA SV 仅在该季度就实现了 1670 万美元的净销售额，这表明，儘管面临经济障碍，但已获批准和核准的产品。

市场挑战

已通过核准疗法的高昂费用和不完善的报销政策是限制全球爱滋病相关脂肪代谢障碍市场发展的主要阻碍因素。这些经济障碍导致临床治疗需求与患者实际购买力之间存在巨大差距。由于脂肪代谢障碍的治疗通常被视为次要干预措施，远不及挽救生命的抗逆转录病毒疗法，因此在许多地区，保险覆盖范围有限甚至无法覆盖。由此，製造商难以打入中低收入市场，因为这些市场的医疗资金严格用于病毒抑制等基本治疗，即使认证核可药具有临床疗效，也难以广泛应用。

鑑于全球需要长期管理的患者群体规模庞大，这种财务限制尤为严峻。虽然理论上市场机会巨大，但实际上，高流行地区的经济挑战限制了其发展，并有效限制了潜在的产生收入。根据联合国爱滋病规划署（UNAIDS）的数据，到2024年，全球将有约4,080万人感染爱滋病毒。如此庞大的患者群体代表着巨大的未满足需求，但只要高昂的自付费用和不完善的报销体系继续阻碍大多数感染者获得治疗，市场就无法充分利用这一需求。

市场趋势

随着先进的生长激素释放因子製剂的商业化，市场格局正在重塑。这些製剂透过改进给药系统，优先考虑提高患者的依从性。虽然传统治疗方法已证实具有临床疗效，但该产业目前正向下一代更容易使用的方案转型，这些方案可显着减轻长期生存者每日用药的负担。这项进步解决了慢性HIV治疗中「治疗疲劳」这一重大挑战，并透过简化复杂的治疗方案，促进了可持续的治疗效果。根据Theratechnologies公司于2025年3月发布的“2025年第一季财务业绩”，美国FDA核准了tesamorelin的新製剂EGRIFTA WR（F8製剂），用于治疗内臟脂肪过多，这标誌着在优化该患者群体的长期代谢管理方面迈出了重要一步。

同时，能够提供持久结构修復的再生生物刺激剂的广泛应用，推动了微创皮肤填充剂的普及。与传统的透明质酸製剂不同，聚左旋乳酸等製剂透过刺激自身胶原蛋白的生成，为脸部脂肪萎缩提供了一种更持久的生理解决方案，并占据了显着的市场份额。这个细分市场已成为高德美集团核心医美产品组合的重要收入来源，凸显了再生医学的商业性趋势。根据高德美集团于2025年3月发布的2024年度报告，该公司实现了创纪录的44.1亿美元净销售额，其旗舰生物刺激剂品牌Sculptra是注射美容领域的主要成长引擎。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球爱滋病相关脂肪萎缩市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按类型（药物治疗、美容矫正治疗）
    • 给药途径（口服、注射、其他）
    • 按分销管道（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美HIV相关脂肪萎缩市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲爱滋病毒相关脂肪萎缩市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区爱滋病相关脂肪萎缩市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲爱滋病毒相关脂肪萎缩市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

10. 南美洲爱滋病毒相关脂肪萎缩市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球爱滋病相关脂肪萎缩市场：SWOT分析

第十四章 波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Theratechnologies Inc
  • Amryt Pharmaceuticals, Inc.
  • Fawn Incorporation
  • Abbott Laboratories, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Bayer AG
  • Novartis Pharmaceuticals Corporation
  • AstraZeneca Plc
  • GlaxoSmithKline Plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17294

The Global HIV-associated Lipodystrophy Market is projected to expand from USD 185.82 Million in 2025 to USD 228.62 Million by 2031, registering a CAGR of 3.52%. Defined as a metabolic syndrome involving abnormal fat redistribution such as lipoatrophy and lipohypertrophy, this condition frequently arises as an adverse reaction to antiretroviral regimens. Growth is primarily driven by the sustained rise in the global HIV-positive population and the extensive scale-up of antiretroviral therapy (ART) programs, which have extended patient life expectancy and increased exposure to long-term side effects. Furthermore, the clinical necessity to address cardiovascular risks linked to metabolic irregularities reinforces the demand for effective management strategies beyond mere aesthetic concerns.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 185.82 Million
Market Size 2031USD 228.62 Million
CAGR 2026-20313.52%
Fastest Growing SegmentDrug Treatment
Largest MarketNorth America

However, market expansion is significantly impeded by the high cost of approved therapeutics and insufficient reimbursement frameworks, which restrict access for patients in low-to-middle-income regions. This economic obstacle remains a critical challenge despite the growing demographic requiring continuous care. According to UNAIDS, approximately 31.6 million individuals globally were accessing antiretroviral therapy by the end of 2024, highlighting a substantial increase in the population potentially at risk of developing treatment-associated lipodystrophy.

Market Driver

The rising global prevalence of HIV infection acts as the fundamental catalyst for market demand, as an increasing number of long-term survivors correlates directly with a higher incidence of metabolic complications. With antiretroviral therapies extending lifespans, patients remain on life-saving regimens for longer periods, thereby accumulating the risk of developing adverse fat redistribution syndromes like lipoatrophy and lipohypertrophy. This expanding patient base generates a continuous medical need for interventions to manage these chronic side effects. As per the UNAIDS 'Fact Sheet 2024' released in July 2024, roughly 39.9 million people globally were living with HIV in 2023, representing a massive patient pool potentially requiring care. Additionally, the Centers for Disease Control and Prevention reported in 2024 that an estimated 1.2 million people in the United States were living with HIV at the end of 2022, highlighting significant demand in high-value regional markets.

Concurrently, advancements in novel therapeutic agents and dermal fillers are accelerating revenue growth by evolving treatment options from basic management to effective aesthetic and metabolic restoration. The commercial availability of targeted growth hormone-releasing factors and specialized volumizing fillers has encouraged adoption among patients aiming to mitigate the stigmatizing physical changes associated with the condition. This sector is demonstrating strong financial results, indicating a willingness among healthcare systems and patients to invest in these solutions. For instance, Theratechnologies Inc. reported in their 'Q3 2024 Earnings Call Transcript' from October 2024 that net sales of EGRIFTA SV, an injectable for reducing excess abdominal fat in HIV-infected patients, reached USD 16.7 million in that quarter alone, proving that efficacious, approved products drive industry expansion despite economic hurdles.

Market Challenge

The exorbitant costs of approved therapeutics combined with inadequate reimbursement policies serve as major restraints on the Global HIV-associated Lipodystrophy Market. These economic barriers create a substantial gap between the clinical necessity for treatment and the actual purchasing power of the affected population. Because lipodystrophy management is frequently classified as a secondary intervention relative to life-saving antiretroviral therapy, insurance coverage is often restricted or unavailable in many jurisdictions. As a result, manufacturers struggle to penetrate low-to-middle-income markets where healthcare funds are rigorously allocated toward essential viral suppression, hindering the widespread uptake of approved drugs despite their clinical effectiveness.

This financial constraint is particularly acute given the immense scale of the global patient population requiring long-term management. While the market opportunity is theoretically extensive, it is practically limited by affordability challenges in high-burden regions, effectively capping potential revenue generation. According to UNAIDS, there were approximately 40.8 million people living with HIV worldwide in 2024. This vast patient base represents a significant unmet need, yet the market is unable to fully capitalize on this demand as long as high out-of-pocket costs and reimbursement deficiencies make treatments inaccessible for the majority of individuals living with the condition.

Market Trends

The market landscape is being reshaped by the commercialization of advanced growth hormone-releasing factor formulations that prioritize patient adherence through improved delivery systems. Although earlier therapies demonstrated clinical efficacy, the industry is now shifting toward next-generation, user-friendly options that significantly alleviate the logistical burden of daily administration for long-term survivors. This progression tackles the critical challenge of "treatment fatigue" in chronic HIV care, promoting sustained therapeutic outcomes by simplifying complex regimens. According to the 'First Quarter 2025 Financial Results' from Theratechnologies Inc. in March 2025, the U.S. FDA approved EGRIFTA WR, a new F8 formulation of tesamorelin designed to treat excess visceral abdominal fat, marking a significant step forward in optimizing long-term metabolic management for this patient group.

Simultaneously, the rising adoption of minimally invasive dermal fillers is being driven by a surge in regenerative biostimulators that provide durable structural restoration surpassing transient volume correction. Unlike traditional hyaluronic acid alternatives, agents such as poly-L-lactic acid are securing substantial market share by stimulating the host's own collagen production, offering a more permanent physiological solution for facial lipoatrophy. This sub-segment has become a crucial revenue driver for major aesthetic portfolios, confirming the commercial trend toward regenerative medicine. As noted in the 'Annual Report 2024' by Galderma Group AG in March 2025, the company achieved record net sales of USD 4.41 billion, with its flagship biostimulator brand Sculptra acting as a primary growth engine within the injectable aesthetics category.

Key Market Players

  • Theratechnologies Inc
  • Amryt Pharmaceuticals, Inc.
  • Fawn Incorporation
  • Abbott Laboratories, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Bayer AG
  • Novartis Pharmaceuticals Corporation
  • AstraZeneca Plc
  • GlaxoSmithKline Plc

Report Scope

In this report, the Global HIV-associated Lipodystrophy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HIV-associated Lipodystrophy Market, By Type

  • Drug Treatment
  • Cosmetic Corrective Treatment

HIV-associated Lipodystrophy Market, By Route of Administration

  • Oral
  • Injectables
  • Others

HIV-associated Lipodystrophy Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

HIV-associated Lipodystrophy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HIV-associated Lipodystrophy Market.

Available Customizations:

Global HIV-associated Lipodystrophy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global HIV-associated Lipodystrophy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Drug Treatment, Cosmetic Corrective Treatment)
    • 5.2.2. By Route of Administration (Oral, Injectables, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America HIV-associated Lipodystrophy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States HIV-associated Lipodystrophy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada HIV-associated Lipodystrophy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico HIV-associated Lipodystrophy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe HIV-associated Lipodystrophy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany HIV-associated Lipodystrophy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France HIV-associated Lipodystrophy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom HIV-associated Lipodystrophy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy HIV-associated Lipodystrophy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain HIV-associated Lipodystrophy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific HIV-associated Lipodystrophy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China HIV-associated Lipodystrophy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India HIV-associated Lipodystrophy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan HIV-associated Lipodystrophy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea HIV-associated Lipodystrophy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia HIV-associated Lipodystrophy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa HIV-associated Lipodystrophy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia HIV-associated Lipodystrophy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE HIV-associated Lipodystrophy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa HIV-associated Lipodystrophy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America HIV-associated Lipodystrophy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil HIV-associated Lipodystrophy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia HIV-associated Lipodystrophy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina HIV-associated Lipodystrophy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global HIV-associated Lipodystrophy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Theratechnologies Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amryt Pharmaceuticals, Inc.
  • 15.3. Fawn Incorporation
  • 15.4. Abbott Laboratories, Inc.
  • 15.5. Lupin Pharmaceuticals, Inc.
  • 15.6. Pfizer Inc.
  • 15.7. Bayer AG
  • 15.8. Novartis Pharmaceuticals Corporation
  • 15.9. AstraZeneca Plc
  • 15.10. GlaxoSmithKline Plc

16. Strategic Recommendations

17. About Us & Disclaimer